In brief
In a recent study, Consumer New Zealand tested 10 popular sunscreens and found that only three met their labeled Sun Protection Factor (SPF) claims. One high‑priced SPF50 product was measured at only SPF14, yet all products passed broad‑spectrum criteria. The results underline gaps in testing frequency rules and raise concerns about consumer protection in a country with one of the world’s highest skin‑cancer rates.
On Friday, New Zealand’s consumer advocacy group Consumer NZ released the findings of an independent test on ten sunscreens commonly found in local stores, revealing that seven of the products failed to deliver the sun protection factor (SPF) they claim on their labels. The most striking finding was that a product labelled SPF 50 provided only SPF 14 in laboratory analysis.
All ten sunscreens tested were required to contain a broad‑spectrum claim, meaning they protect against both ultraviolet‑A and ultraviolet‑B rays. According to the report, each product met this standard, but only three of them met their advertised SPF ratings. Prices for the tested sunscreens ranged from $4 to $76 per 100 ml, indicating that consumers of all budgets were potentially at risk of receiving inadequate protection.
Background of the Testing
Consumer NZ’s study followed a similar investigation carried out a few years earlier that uncovered a reliance on outdated test reports. The agency highlighted that some brands have managed to submit third‑party test documentation that was several years old to satisfy regulatory or consumer requirements, a practice that may no longer reflect current formulae.
The report further notes that, while New Zealand has stringent safety standards for cosmetics, the country lacks explicit regulations prescribing how frequently sunscreens must be re‑tested. "New Zealand has one of the highest skin cancer and melanoma rates in the world," said Belinda Castles, a researcher at Consumer NZ. "Sunscreen plays an important role in preventing skin cancer."
"New Zealand has one of the highest skin cancer and melanoma rates in the world, and sunscreen plays an important role in preventing skin cancer,"
Castles added that the findings underline the need for continuous, independent verification of product claims, as the quality and effectiveness of sunscreens can degrade with changes in formulation or storage conditions.
Questions Raised by the Findings
One of the primary concerns raised by the study is the discrepancy between labeled and measured SPF values. An SPF 50 product meeting only SPF 14 territory suggests that the label may mislead consumers about how much protection they are receiving. For an individual spending only $76 for 100 ml of sunscreen thought to offer high‑level protection, the real protection could be a fraction of the advertised level, potentially exposing them to harmful ultraviolet exposure.
Consumer NZ’s investigation also found that, even though they all met broad‑spectrum testing criteria, a failure to meet SPF claims could still mean that the products either contain insufficient active ingredients or that those ingredients are not properly distributed in the formulation. The agency is seeking clarification from several manufacturers on how their products are tested and what data are used to support their claims.
Beyond the technical explanations, there are regulatory questions. Consumer NZ points out that, in the absence of mandatory periodic testing, consumers are largely left to trust cosmetic labels and the reputations of the brands. The study raised the question of whether a regulatory framework might be required to impose maximum intervals for re‑testing or mandatory third‑party validation before products can be marketed again.
In discussions with regulators, Consumer NZ suggested that implementing a schedule for testing could accentuate the industry’s accountability. The agency has signed up for a series of follow‑up products testing, but no official timeline exists for the entire sunscreen market.
Following the release of the data, some consumers have highlighted that the discrepancy could have serious health implications. A member of the public posted on social media, "I bought the ‘SPF 50’ for my children’s sun protection but seeing it was actually SPF 14 is alarming. I feel misled."
"I bought the ‘SPF 50’ for my children’s sun protection but seeing it was actually SPF 14 is alarming. I feel misled,"
Such reactions underscore the need for clear labeling and verified claims, particularly for a population that spends an average of 4.4 minutes per day exposed to the sun during peak hours, according to national health surveys. The study has prompted discussions in parliament, where health ministers have stated that any new legislation on sunscreen testing would need to balance consumer safety with industry innovation.
Meanwhile, the marketing strategies of sun‑protection brands are also under scrutiny. Some companies claimed to be using newer UVA‑filter technologies that ostensibly provide higher protection. Vaccinated with statements that are not yet laboratory verified, these marketing claims raise the question of whether evidence can be better integrated into product labeling requirements.
From the manufacturers’ perspective, there is an acknowledgment that a single test may not capture the full spectrum of product performance across varying physical conditions. One brand spokesperson said, "We regularly conduct dermal and chemical assessments, but we recognize the importance of aligning these with regulatory guidance." That statement highlights the industry's willingness to address the issues while calling for clearer rules that define what acceptable testing frequency looks like.
"We regularly conduct dermal and chemical assessments, but we recognize the importance of aligning these with regulatory guidance,"
Beyond the immediate concern of under‑performance, the findings could have wider influence on consumer trust in the sunscreen market. Consumer NZ’s investigation often runs in parallel with other consumer testing programs that have highlighted product performance gaps, such as testing of moisturizers or anti‑aging creams. This new data feeds into a larger pattern that calls for increased enforcement of safety and efficacy standards across New Zealand’s cosmetic industry.
In response to the findings, Consumer NZ has called for an independent review led by a panel of dermatologists and toxicologists. The agency also requested that the Ministry of Health consider enacting legislation that mandates periodic testing for all sunscreens sold on the New Zealand market, regardless of the manufacturers' reliance on older data.
As the sun‑scorching summer approaches, the question of whether consumers can rely on the product labels becomes paramount. If an SPF fifty product only delivers SPF fourteen, then plain and simple, the label is misleading. But the larger question remains: Will the regulatory approach keep pace with rapid changes in product development and consumer expectations? The outcome will likely shape the direction of New Zealand's sunscreen market in the years to come.
